Norway · Delayed Price · Currency is NOK Navamedic ASA Statistics
Total Valuation
Navamedic ASA has a market cap or net worth of NOK 351.33 million. The enterprise value is 481.38 million.
| Market Cap | 351.33M |
| Enterprise Value | 481.38M |
Important Dates
The last earnings date was Friday, August 14, 2026.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Navamedic ASA has 23.98 million shares outstanding. The number of shares has increased by 27.84% in one year.
| Current Share Class | 23.98M |
| Shares Outstanding | 23.98M |
| Shares Change (YoY) | +27.84% |
| Shares Change (QoQ) | +2.55% |
| Owned by Insiders (%) | 11.90% |
| Owned by Institutions (%) | 33.42% |
| Float | 10.93M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 235.91 |
| PS Ratio | 0.61 |
| PB Ratio | 1.15 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 27.71 |
| P/OCF Ratio | 23.07 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.59, with an EV/FCF ratio of 37.97.
| EV / Earnings | n/a |
| EV / Sales | 0.84 |
| EV / EBITDA | 9.59 |
| EV / EBIT | 114.83 |
| EV / FCF | 37.97 |
Financial Position
The company has a current ratio of 1.47, with a Debt / Equity ratio of 0.60.
| Current Ratio | 1.47 |
| Quick Ratio | 0.74 |
| Debt / Equity | 0.60 |
| Debt / EBITDA | 3.64 |
| Debt / FCF | 14.44 |
| Interest Coverage | 0.25 |
Financial Efficiency
Return on equity (ROE) is -8.86% and return on invested capital (ROIC) is 0.95%.
| Return on Equity (ROE) | -8.86% |
| Return on Assets (ROA) | 0.46% |
| Return on Invested Capital (ROIC) | 0.95% |
| Return on Capital Employed (ROCE) | 0.84% |
| Weighted Average Cost of Capital (WACC) | 6.07% |
| Revenue Per Employee | 15.11M |
| Profits Per Employee | -609,553 |
| Employee Count | 38 |
| Asset Turnover | 1.01 |
| Inventory Turnover | 3.24 |
Taxes
In the past 12 months, Navamedic ASA has paid 1.54 million in taxes.
| Income Tax | 1.54M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -32.95% in the last 52 weeks. The beta is 0.22, so Navamedic ASA's price volatility has been lower than the market average.
| Beta (5Y) | 0.22 |
| 52-Week Price Change | -32.95% |
| 50-Day Moving Average | 16.29 |
| 200-Day Moving Average | 19.62 |
| Relative Strength Index (RSI) | 31.74 |
| Average Volume (20 Days) | 80,576 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Navamedic ASA had revenue of NOK 574.31 million and -23.16 million in losses. Loss per share was -1.04.
| Revenue | 574.31M |
| Gross Profit | 226.17M |
| Operating Income | 4.19M |
| Pretax Income | -21.62M |
| Net Income | -23.16M |
| EBITDA | 47.19M |
| EBIT | 4.19M |
| Loss Per Share | -1.04 |
Balance Sheet
The company has 52.95 million in cash and 183.00 million in debt, with a net cash position of -130.05 million or -5.42 per share.
| Cash & Cash Equivalents | 52.95M |
| Total Debt | 183.00M |
| Net Cash | -130.05M |
| Net Cash Per Share | -5.42 |
| Equity (Book Value) | 306.09M |
| Book Value Per Share | 12.76 |
| Working Capital | 74.89M |
Cash Flow
In the last 12 months, operating cash flow was 15.23 million and capital expenditures -2.55 million, giving a free cash flow of 12.68 million.
| Operating Cash Flow | 15.23M |
| Capital Expenditures | -2.55M |
| Depreciation & Amortization | 43.00M |
| Net Borrowing | 69.09M |
| Free Cash Flow | 12.68M |
| FCF Per Share | 0.53 |
Margins
Gross margin is 39.38%, with operating and profit margins of 0.73% and -4.03%.
| Gross Margin | 39.38% |
| Operating Margin | 0.73% |
| Pretax Margin | -3.76% |
| Profit Margin | -4.03% |
| EBITDA Margin | 8.22% |
| EBIT Margin | 0.73% |
| FCF Margin | 2.21% |
Dividends & Yields
Navamedic ASA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -27.84% |
| Shareholder Yield | -27.84% |
| Earnings Yield | -6.59% |
| FCF Yield | 3.61% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for Navamedic ASA is 21.00, which is 43.84% higher than the current price. The consensus rating is "Buy".
| Price Target | 21.00 |
| Price Target Difference | 43.84% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 6.90% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Navamedic ASA has an Altman Z-Score of 1.78 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.78 |
| Piotroski F-Score | 5 |